Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Fourth quarter contract value or CV grew 1% year over year. Outside the US federal government, CV grew 4%. In the quarter, ...